<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970798</url>
  </required_header>
  <id_info>
    <org_study_id>6356-005</org_study_id>
    <nct_id>NCT03970798</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin</brief_title>
  <official_title>A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the influence of repeated oral doses of KW-6356 on
      the pharmacokinetics of index substrates for CYP3A4/5, CYP1A2 and BCRP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean ratio of the major pharmacokinetic parameter (AUC0-t) of the index substrates in combination with or without KW-6356</measure>
    <time_frame>Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean ratio of the major pharmacokinetic parameters (Cmax) of the index substrates in combination with or without KW-6356</measure>
    <time_frame>Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean ratio of the major pharmacokinetic parameters (AUC0-âˆž) of the index substrates in combination with or without KW-6356</measure>
    <time_frame>Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (tmax) of the index substrates</measure>
    <time_frame>Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (CL/F) of the index substrates</measure>
    <time_frame>Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (Vz/F) of the index substrates</measure>
    <time_frame>Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (t1/2) of the index substrates</measure>
    <time_frame>Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of the index substrates</measure>
    <time_frame>Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of KW-6356</measure>
    <time_frame>Starting around 2 hours before intake of KW-6356 and continued until 24 hours after the last dose of KW-6356</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Starting 24 or 48 hours before intake of the index substrates and continued until 8 days after the last dose of KW-6356</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>KW-6356/Healthy Japanese adult male subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: intake of the index substrates at Day 1 (Cohort 1: midazolam, Cohort 2: caffeine + rosuvastatin) followed by Period 2: intake of KW-6356 at Day 4-13, intake of the index substrates at Day 11</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.</description>
    <arm_group_label>KW-6356/Healthy Japanese adult male subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.</description>
    <arm_group_label>KW-6356/Healthy Japanese adult male subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.</description>
    <arm_group_label>KW-6356/Healthy Japanese adult male subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-6356</intervention_name>
    <description>In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.</description>
    <arm_group_label>KW-6356/Healthy Japanese adult male subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Individuals having issued written consent to this study at their own discretion

          2. Japanese males aged 20 to 44 years at the time of informed consent

          3. Body mass index (BMI) of 18.5 to &lt;25.0 at screening

          4. Resting pulse rate of 40 to 100 bpm, systolic blood pressure of 90 to 139 mmHg, and
             diastolic blood pressure of 40 to 89 mmHg when measured in the supine position at
             screening

        Exclusion Criteria:

          1. Individuals with any current disease requiring treatment

          2. Individuals having drug allergy or its history

          3. Individuals having psychiatric disease or its history

          4. Positive results for any of the following infection-related items examined at
             screening: hepatitis B surface (HBs) antigen, HBs antibody, hepatitis B core (HBc)
             antibody, hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV)
             antigen/antibody, human T-lymphotropic virus (HTLV)-1 antibody, rapid plasma reagin
             (PRP) test, Treponema pallidum (TP) antibody.

          5. Individuals with clinically significant abnormality detected on 12-lead
             electrocardiogram (ECG) recorded prior to the first dose of index substrate.

          6. Individuals categorized as patients listed in the warnings or contraindications
             section of the package insert of any of the relevant index substrates (see separate
             protocol annex 6-8)

          7. Individuals having used any drug (including over-the-counter [OTC] drugs, topical
             agents, vitamin preparations, health supplements, and Chinese herbal medicines) within
             2 weeks prior to the first dose of index substrate.

          8. Individuals having consumed grapefruit (including any food or beverage containing
             grapefruit) or any food or beverage containing St John's wort within 1 week prior to
             the first dose of index substrate.

          9. Individuals having smoked or used smoking cessation agents (including chewing or
             eating of nicotine-containing products and application of nicotine patches) within 4
             weeks prior to the first dose of index substrate.

         10. Individuals having received inpatient treatment or surgery within 12 weeks prior to
             the first dose of index substrate.

         11. Individuals having participated in a clinical study of a pharmaceutical product or a
             medical device or any equivalent study and used the investigational product or the
             unapproved medical device within 16 weeks prior to the first dose of index substrate.

         12. Individuals having undergone collection of â‰¥400 mL of blood within 12 weeks prior to
             the first dose of index substrate or â‰¥200 mL of blood within 4 weeks prior to the
             first dose of index substrate (for blood donation or clinical trial, etc.) or pheresis
             donation (plateletpheresis or plasmapheresis donation) within 2 weeks prior to the
             first dose of index substrate.

         13. Individuals having issued no consent to adoption of any appropriate contraceptive
             method during a period from day of admission to 12 weeks after the final dose of the
             study drug. The appropriate contraceptive method is defined as sexual abstinence or
             use of 2 of the following contraceptive devices: condom, oral contraceptives,
             intrauterine device, and pessary.

         14. Individuals having received KW-6356 before.

         15. Other individuals unsuitable for participating in the study in the opinion of the
             investigator or subinvestigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fukuoka Mirai Hospital Clinical Research Center</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

